Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in neutrophils | 0.75 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 54 | 0.79 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 8233
Sealed predictions
- RPH3A in dopamine neurons, braak+0.03 (p 0.947) → +0.10 (p 0.802)receipt 8240
Swarm cases
receipt 8240: RPH3A in dopamine neurons, braak
- power
- full sample +0.07 (p 0.781, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.07 (p 0.781, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.11 (p 0.671, n 18). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.20, sign flips 2; without severely affected donors +0.07 (p 0.781, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RPH3A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts